Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Fig. 2

Arm-level scatter plot of surrogate and true endpoints. (a) Arm-level scatter plot of ORR and median OS. The Spearman’s rho coefficient is 0.700; (b) Arm-level scatter plot of ORR and median PFS. The Spearman’s rho coefficient is 0.831; (c) Arm-level scatter plot of median PFS and median OS. The Spearman’s rho coefficient is 0.755. Each arm is represented by a bubble whose radius is proportional to the study sample size. The bubble colour represents the therapy type of the arm

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us